Chemed Corp (CHE) Q1 2026 Earnings Call Transcript

Why It Matters

The results underscore pressure on Chemed’s two core businesses from regulatory caps and insurance scrutiny, while strategic initiatives aim to restore profitability and fuel growth. Investor confidence hinges on the company’s ability to rebalance patient mix and improve Roto‑Rooter’s lead generation efficiency.

Key Takeaways

• VITAS admissions up 6% to 17,419
• Florida Medicare cap liability down $25 million
• Roto‑Rooter write‑offs exceed 4.5% of revenue
• Paid lead cost $90, requiring 1.5‑2 leads per job
• Manatee County CON adds 3,000 Medicare hospice patients

Pulse Analysis

Chemed’s VITAS segment operates in a tightly regulated hospice market where Medicare caps can dramatically affect cash flow. The company’s recent success in eliminating the Florida cap liability—saving roughly $25 million—removes a major headwind, but the higher proportion of hospital‑based short‑stay admissions has compressed margins. Analysts expect VITAS to rebalance its admission mix toward community sources, a move that should lift average daily census and improve reimbursement rates as the demographic shift toward an aging population fuels hospice demand across Florida and beyond.

Roto‑Rooter faces a different set of challenges rooted in the residential plumbing and water‑restoration business. Increased insurance scrutiny has driven implicit price concessions and write‑offs above 4.5% of gross revenue, while natural search traffic has stalled, forcing the company to rely on costly paid leads. The recent partnership with an exclusive SEO firm aims to restore organic visibility, and the rollout of commercial business managers is designed to capture higher‑margin commercial contracts. These initiatives, combined with centralized billing for water‑restoration services, are projected to generate a $4‑$6 million tailwind later in 2026.

Overall, Chemed’s 2026 outlook hinges on execution across both segments. The VITAS expansion into Manatee County adds a new catchment area of roughly 3,000 Medicare hospice patients, supporting long‑term revenue growth. Meanwhile, Roto‑Rooter’s focus on technology‑driven billing improvements and targeted lead acquisition seeks to reverse recent margin erosion. Investors will watch the second‑half earnings closely, as the company’s guidance suggests that the bulk of the recovery—both top‑line and EBITDA—will materialize after the mid‑year point. Success in these areas could reinforce Chemed’s dividend‑friendly capital return strategy and sustain its share‑repurchase program.